“Necessity is the mother of invention,” says
the ancient proverb. In my opinion, the
corollary is: “disruption is the matriarch of transformation,” especially for
the Life-Sciences industries.
The COVID-19 epidemic has been the biggest global disruption
in our generation. It represents a watershed moment for transformation
throughout our industry.
Disruption is the new normal. This new paradigm is forcing Life-Science companies to re-imagine the way they operate; transforming and accelerating product development, regulatory review, manufacturing, and distribution cycles aimed at improving patient outcomes.
Remote Evaluations, Grading Industry on a Curve and Using AI to Predict Site Inspection Scores
By: Axendia Staff
The FDA issued its latest report on the State of Pharmaceutical Quality. In the report, the Agency describes Pharmaceutical Quality as the ability of the pharmaceutical manufacturing industry to deliver quality drug products to U.S. patients and consumers. In addition, FDA defines quality drug products as those that are safe and effective and free of contamination and defects. It is worth noting the absence of the word “compliant” in these definitions.
Hidden among Hand Sanitizer recall data were a number of significant developments on FDA’s regulatory approach.
This Brief represents Axendia’s analysis and insights on FDA’s Report on the State of Pharmaceutical Quality.
“The United States faces persistent and increasingly sophisticated malicious cyber campaigns that threaten the public sector, the private sector, and ultimately the American people’s security and privacy,” begins the May 2021 presidential executive order on improving the nation’s cybersecurity. Recent crippling cyberattacks on the Colonial pipeline and JBS Foods, and the SolarWinds and Microsoft Exchange hacks, among others, have painfully highlighted the fragility of the information and operational technologies on which the modern world so heavily relies.
IBM and Fraunhofer Unveil Fastest Quantum Computer in Europe – Event Brief
By: Eric M. Luyer, Industry Research Analyst Axendia Inc.
Axendia Inc. was present on 15-JUN-2021 at the official inauguration of the first IBM Quantum Computer in Europe by IBM and the Fraunhofer-Gesellschaft. The setting was a compact virtual live event with highly distinguished guest speakers: Dr. Angela Merkel – German Chancellor, Dr. Arvind Krishna – CEO and Chairman IBM, Prof. Dr. Reimund Neugebauer – President of the Fraunhofer – Gesellschaft e.V. as well as various representatives of large industries such as Trumpf, Bosch, BASF, BMW and others.
was recently briefed by Mike Jovanis, vice president of Vault Quality and Kent
Malmros, senior director of Vault Training at Veeva Systems. Veeva
Systems (www.veeva.com) is a cloud computing company focused on the
pharmaceutical and life sciences industry.
Veeva Vault Quality customers continue to increase in numbers and now include 14 of the top 20 largest pharmaceutical companies. Leading companies around the world are adopting a cloud culture to lower the cost of implementation and ownership, enable collaboration with external partners, and simplify business processes. To date, more than 175 biopharma, contract manufacturers, generics, and medtech companies, have adopted Vault QMS to streamline and automate quality processes. “As a trusted partner, Veeva has been collaborating closely with life sciences companies globally on their digital quality initiatives,” said Mike Jovanis, vice president, Veeva Vault Quality. “We are committed to customer success and will continue to deliver customer-focused innovation across product development and manufacturing.”